Iconovo AB has completed a directed share issue of SEK 75 million

The Board of Directors of Iconovo AB (publ) (”Iconovo” or the ”Company”) has, pursuant to the authorisation granted by the Annual General…

Iconovo sets ambitious financial targets for 2026

Iconovo AB (publ), which develops complete inhalation products for a global market, today announces its five-year goals for the business. By…

Iconovo and Respiratorius sign agreement for development of inhalation product to treat COPD

Iconovo AB (publ), which develops complete inhalation products for a global market, and Respiratorius AB (publ), which develops drug candidates…

Iconovo extends agreement with Amneal for generic Symbicort to cover key markets U.S. and China, as well as Nordic sales rights

Iconovo AB (publ), which develops complete inhalation products for a global market, today announced that its collaboration with the U.S. pharmaceutical…

Abbreviated interim report January – March 2021

 Strategic innovation generates new agreements Key figures in TSEK unless otherwise indicated  Jan-Mar 2021 Jan-Mar 2020 Jan-Dec 2020 Net…

Iconovo´s new inhaler ICOpre® to be presented at RDD 2021 workshop

First granted ICOone® patent in the United States

United States Patent and Trademark Office has announced the intention to grant a patent (Notice of Allowance) regarding Iconovo’s inhalation device…

Iconovo signs agreement with ISR for the development of inhaled covid-19 vaccine

Iconovo AB (publ), a company developing complete inhalation products for a global market, today announced that it has signed an agreement with…

Abbreviated interim report january – december 2020

50 percent growth in 2020 and ambitious goals for the future Key figures in TSEK unless otherwise indicated  Oct-Dec 2020 Oct-Dec…

VD Johan Wäborg förvärvar aktier för 1 100 000 SEK (only in Swedish)

Johan Wäborg, VD i Iconovo AB (publ), har förvärvat 20 000 aktier i bolaget till kursen 55 SEK, totalt 1 100 000 SEK. Förvärvet gjordes från…